249 related articles for article (PubMed ID: 20117883)
21. Cancer of the gastroesophageal junction: combined modality therapy.
Ilson DH
Surg Oncol Clin N Am; 2006 Oct; 15(4):803-24. PubMed ID: 17030275
[TBL] [Abstract][Full Text] [Related]
22. Overview of multimodal therapy for adenocarcinoma of the esophagogastric junction.
Hosoda K; Yamashita K; Katada N; Watanabe M
Gen Thorac Cardiovasc Surg; 2015 Oct; 63(10):549-56. PubMed ID: 26232357
[TBL] [Abstract][Full Text] [Related]
23. Trimodality therapy without a platinum compound for localized carcinoma of the esophagus and gastroesophageal junction.
Ajani JA; Correa AM; Walsh GL; Komaki R; Lee JH; Vaporciyan AA; Rice DC; Yao JC; Maru DM; Hofstetter WL; Phan AT; Swisher SG
Cancer; 2010 Apr; 116(7):1656-63. PubMed ID: 20143431
[TBL] [Abstract][Full Text] [Related]
24. Esophagogastric junction and gastric adenocarcinoma: neoadjuvant and adjuvant therapy, and future directions.
Sandler S
Oncology (Williston Park); 2014 Jun; 28(6):505-12. PubMed ID: 25134325
[TBL] [Abstract][Full Text] [Related]
25. Adenocarcinoma of the esophagogastric junction: the pattern of metastatic lymph node dissemination as a rationale for elective lymphatic target volume definition.
Meier I; Merkel S; Papadopoulos T; Sauer R; Hohenberger W; Brunner TB
Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1408-17. PubMed ID: 18374226
[TBL] [Abstract][Full Text] [Related]
26. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome.
Ajani JA; Mansfield PF; Crane CH; Wu TT; Lunagomez S; Lynch PM; Janjan N; Feig B; Faust J; Yao JC; Nivers R; Morris J; Pisters PW
J Clin Oncol; 2005 Feb; 23(6):1237-44. PubMed ID: 15718321
[TBL] [Abstract][Full Text] [Related]
27. American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma.
Rizk NP; Venkatraman E; Bains MS; Park B; Flores R; Tang L; Ilson DH; Minsky BD; Rusch VW;
J Clin Oncol; 2007 Feb; 25(5):507-12. PubMed ID: 17290058
[TBL] [Abstract][Full Text] [Related]
28. It is time for a proper staging system for adenocarcinoma of the gastroesophageal junction.
Pedrazzani C; de Manzoni G; Marrelli D; Roviello F
J Clin Oncol; 2007 Mar; 25(7):907-8; author reply 908-9. PubMed ID: 17327616
[No Abstract] [Full Text] [Related]
29. Advances in the treatment of patients with gastric adenocarcinoma.
Foukakis T; Lundell L; Gubanski M; Lind PA
Acta Oncol; 2007; 46(3):277-85. PubMed ID: 17450463
[TBL] [Abstract][Full Text] [Related]
30. Esophagogastric junction adenocarcinoma according to Siewert classification in Taiwan.
Fang WL; Wu CW; Chen JH; Lo SS; Hsieh MC; Shen KH; Hsu WH; Li AF; Lui WY
Ann Surg Oncol; 2009 Dec; 16(12):3237-44. PubMed ID: 19636628
[TBL] [Abstract][Full Text] [Related]
31. [Adenocarcinoma of the esophagogastric junction (AEG-tumor). Review of the literature].
Pilco J; Stein J
Rev Gastroenterol Peru; 2006; 26(2):194-9. PubMed ID: 16865166
[TBL] [Abstract][Full Text] [Related]
32. Patterns of failure following surgical resection for malignant pleural mesothelioma.
Jänne PA; Baldini EH
Thorac Surg Clin; 2004 Nov; 14(4):567-73. PubMed ID: 15559064
[TBL] [Abstract][Full Text] [Related]
33. Preoperative therapy in esophageal cancer.
Ku GY; Ilson DH
Clin Adv Hematol Oncol; 2008 May; 6(5):371-9. PubMed ID: 18516027
[TBL] [Abstract][Full Text] [Related]
34. Lymphatic vessel invasion as a prognostic factor in patients with primary resected adenocarcinomas of the esophagogastric junction.
von Rahden BH; Stein HJ; Feith M; Becker K; Siewert JR
J Clin Oncol; 2005 Feb; 23(4):874-9. PubMed ID: 15681533
[TBL] [Abstract][Full Text] [Related]
35. Multimodality therapy of local regional esophageal cancer.
Kelsen DP
Semin Oncol; 2005 Dec; 32(6 Suppl 9):S6-10. PubMed ID: 16399422
[TBL] [Abstract][Full Text] [Related]
36. Clinical profile of carcinoma stomach at a tertiary care hospital in south India.
Sambasivaiah K; Ibrarullah M; Reddy MK; Reddy PV; Wagholikar G; Jaiman S; Reddy DG; Sarma KV; Hegde GN
Trop Gastroenterol; 2004; 25(1):21-6. PubMed ID: 15303466
[TBL] [Abstract][Full Text] [Related]
37. Controversies in the treatment of local and locally advanced gastric and esophageal cancers.
Cohen DJ; Leichman L
J Clin Oncol; 2015 Jun; 33(16):1754-9. PubMed ID: 25918302
[TBL] [Abstract][Full Text] [Related]
38. Differential pathologic variables and outcomes across the spectrum of adenocarcinoma of the esophagogastric junction.
Reynolds JV; Ravi N; Muldoon C; Larkin JO; Rowley S; O'Byrne K; Hollywood D; O'Toole D
World J Surg; 2010 Dec; 34(12):2821-9. PubMed ID: 20827475
[TBL] [Abstract][Full Text] [Related]
39. The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiation.
Gu Y; Swisher SG; Ajani JA; Correa AM; Hofstetter WL; Liao Z; Komaki RR; Rashid A; Hamilton SR; Wu TT
Cancer; 2006 Mar; 106(5):1017-25. PubMed ID: 16456809
[TBL] [Abstract][Full Text] [Related]
40. Surgical factors influence the outcome after Ivor-Lewis esophagectomy with intrathoracic anastomosis for adenocarcinoma of the esophagogastric junction: a consecutive series of 240 patients at an experienced center.
Ott K; Bader FG; Lordick F; Feith M; Bartels H; Siewert JR
Ann Surg Oncol; 2009 Apr; 16(4):1017-25. PubMed ID: 19189186
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
